⚠️ This AI-generated report synthesizes publicly available information. AI can make mistakes. Please double check information in this report.
Recursion Pharmaceuticals, Inc.
Healthcare | Biotechnology
⚡ Executive Summary
📊 The Bottom Line
Recursion Pharmaceuticals is a clinical-stage biotechnology company leveraging a sophisticated AI-driven platform to accelerate drug discovery. Despite significant collaborations and a diverse clinical pipeline, the company operates at a loss, which is typical for R&D-intensive biotechs, indicating a long path to potential profitability.
⚖️ Risk vs Reward
At its current price, RXRX presents a high-risk, high-reward profile inherent in clinical-stage biotechnology. Substantial upside could materialize with successful pipeline advancements and strategic partnerships, but considerable downside risk persists due to the high failure rate of drug development and ongoing negative profitability.
🚀 Why RXRX Could Soar
- • Successful advancement of its diverse clinical pipeline, particularly REC-4881 for familial adenomatous polyposis, could unlock substantial value and investor confidence through key development milestones.
- • Strategic collaborations with major pharmaceutical companies like Roche & Genentech, Sanofi, and Bayer AG validate its AI-driven drug discovery platform and provide crucial non-dilutive funding.
- • Continued innovation and expansion of its proprietary Recursion OS platform could significantly de-risk future drug development and attract further high-value partnerships and licensing opportunities.
⚠️ What Could Go Wrong
- • Clinical trial failures or unexpected safety issues with any of its drug candidates would severely impact the stock, leading to significant value destruction and investor skepticism.
- • High research and development expenses, coupled with consistent negative operating income and cash flow, indicate a substantial cash burn rate, necessitating future capital raises that could dilute existing shareholders.
- • Intense competition in the biotechnology sector and challenges in securing and defending robust intellectual property could limit market penetration and long-term commercial potential of its therapies.
🏢 Company Overview
💰 How RXRX Makes Money
- • Recursion Pharmaceuticals discovers and develops drug candidates by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery.
- • The company primarily focuses on advancing its clinical-stage pipeline, which includes drug candidates such as REC-4881 for familial adenomatous polyposis and REC-617 for advanced solid tumors.
- • Revenue is currently generated through strategic collaboration agreements with major pharmaceutical partners, with the potential for future drug sales upon successful regulatory approval and commercialization.
🎯 WHY THIS MATTERS
The company's revenue model relies heavily on the successful progression of its drug pipeline through clinical trials and the ability to secure and maintain lucrative pharmaceutical partnerships. This carries inherent risks associated with drug development, yet offers significant upside upon successful commercialization of therapies.
⭐ Competitive Advantage: What Makes RXRX Special
1. AI-Driven Drug Discovery Platform
Recursion utilizes a proprietary 'Recursion OS' platform that integrates AI, machine learning, robotics, and automation to decode biology and chemistry. This allows for the rapid generation and analysis of massive datasets to identify novel drug candidates and accelerate the drug discovery process, potentially reducing costs and timelines significantly compared to traditional methods.
2. Diverse and Expanding Pipeline
The company boasts a broad and diverse pipeline of drug candidates across various therapeutic areas, including oncology and rare diseases, with multiple programs in preclinical to Phase 2. This multi-asset approach diversifies risk associated with individual drug failures and increases the probability of bringing successful treatments to market.
3. Strategic Big Pharma Collaborations
Recursion has established significant partnerships with leading pharmaceutical companies such as Roche/Genentech, Sanofi, and Bayer AG, which include potential deal values exceeding $12B. These collaborations provide substantial funding, non-dilutive capital, and strategic validation of Recursion's platform and pipeline.
🎯 WHY THIS MATTERS
Recursion's unique integration of AI into drug discovery, combined with a diversified pipeline and strong industry partnerships, positions it to potentially disrupt traditional pharmaceutical development. These advantages are crucial for navigating the high-risk, high-reward landscape of biotechnology and achieving long-term success.
👔 Who's Running The Show
Najat Khan
CEO, President & Director
Najat Khan, as CEO, President & Director, leads Recursion Pharmaceuticals with extensive experience in drug discovery and development. Her background is crucial for guiding the company's AI-driven platform and advancing its clinical pipeline to bring new therapies to patients, navigating the complexities of biotech innovation.
⚔️ What's The Competition
The biotechnology sector is highly competitive, characterized by numerous companies vying for market share in drug discovery and development. Recursion Pharmaceuticals faces competition from traditional pharmaceutical giants, other AI-driven biotech firms, and academic institutions, all seeking to develop novel therapies. Differentiation often stems from proprietary technology platforms and clinical trial success.
📊 Market Context
- Total Addressable Market - The global drug discovery market is projected to reach over US$100B by 2030, driven by increasing prevalence of chronic diseases and technological advancements.
- Key Trend - The rapid adoption of artificial intelligence and machine learning is revolutionizing drug discovery, enabling faster identification of drug candidates and personalized medicine.
Competitor
Description
vs RXRX
Exscientia (NASDAQ:EXAI)
A direct rival in AI-driven drug discovery, known for being one of the first to advance an AI-designed molecule into human trials.
Competes directly in leveraging AI for drug discovery, but Recursion emphasizes its large-scale automated wet-lab data generation as a core strength.
Schrödinger (NASDAQ:SDGR)
Focuses on physics-based computational modeling to predict molecular properties and optimize drug candidates for drug discovery.
Strong in molecular prediction, but less focused on the massive automated wet-lab data generation that is a core strength for Recursion's approach.
Insilico Medicine (NASDAQ:IMRX)
An end-to-end AI drug discovery company that has successfully advanced AI-designed molecules into Phase 2 clinical trials.
Employs a similar AI-first approach with a strong pipeline, demonstrating accelerating validation of AI-driven pipelines in the biotechnology industry.
📊 Valuation & Analysis
📈 Wall Street Summary
Analyst Rating Distribution - 5 Hold, 1 Buy, 2 Strong Buy
5
1
2
12-Month Price Target Range
Low Target
US$3
-12%
Average Target
US$7
+94%
High Target
US$10
+195%
Closing: US$3.39 (1 May 2026)
🚀 The Bull Case - Upside to US$10
1. Advancement of Clinical Pipeline
Medium Probability
Successful progression of Recursion's diverse clinical pipeline, particularly key candidates like REC-4881 and REC-617, through advanced trial stages could trigger significant milestone payments and ultimately lead to market approvals, unlocking multi-billion dollar market opportunities.
2. Expansion of AI Platform and Partnerships
High Probability
Continued technological advancements in the Recursion OS and new strategic collaborations with major pharmaceutical companies could accelerate drug discovery, reduce R&D costs, and broaden the platform's application across more therapeutic areas, driving sustained competitive advantage and diversified revenue.
3. De-risking Through Real-World Data Integration
Medium Probability
The integration of real-world data capabilities, such as through the Citeline partnership, can significantly improve clinical trial design and development decisions. This could lead to higher success rates in trials and a more efficient, accelerated path to market for drug candidates.
🐻 The Bear Case - Downside to US$3
1. High Clinical Trial Failure Rate
High Probability
The inherent high failure rate of drug development, especially in early to mid-stage trials, poses a significant risk. Any setbacks or failures in Recursion's current clinical programs could lead to substantial value erosion and investor skepticism.
2. Intense Competition and Intellectual Property Challenges
Medium Probability
Recursion operates in a highly competitive biotechnology landscape. Increased competition or an inability to secure robust patent protection for its discoveries could limit market exclusivity, erode pricing power, and reduce the commercial potential of its drug candidates.
3. Significant and Sustained Cash Burn
High Probability
Recursion Pharmaceuticals consistently reports negative operating income and cash flow, indicating a high burn rate necessary for its extensive R&D efforts. This necessitates future capital raises, which could dilute existing shareholders if not executed favorably.
🔮 Final thought: Is this a long term relationship?
Owning Recursion Pharmaceuticals for a decade hinges on a strong belief in the transformative power of AI in drug discovery and the company's ability to consistently translate this into successful clinical outcomes. The diversified pipeline and strategic partnerships offer some resilience, but the high-risk nature of biotech, coupled with substantial cash burn and fierce competition, means sustained capital is needed. Success requires overcoming numerous clinical hurdles and demonstrating a clear path to profitability over the long term.
📋 Appendix
Financial Performance
Metric
31 Dec 2025
31 Dec 2024
31 Dec 2023
Income Statement
Revenue
US$0.07B
US$0.06B
US$0.04B
Gross Profit
US$0.00B
US$0.01B
US$0.00B
Operating Income
US$-0.65B
US$-0.48B
US$-0.35B
Net Income
US$-0.64B
US$-0.46B
US$-0.33B
EPS (Diluted)
-1.44
-1.69
-1.58
Balance Sheet
Cash & Equivalents
US$0.74B
US$0.59B
US$0.39B
Total Assets
US$1.47B
US$1.45B
US$0.65B
Total Debt
US$0.08B
US$0.11B
US$0.05B
Shareholders' Equity
US$1.13B
US$1.03B
US$0.46B
Key Ratios
Gross Margin
4.4%
22.7%
2.9%
Operating Margin
-872.8%
-819.0%
-797.8%
string
-57.01
-44.81
-70.79
Analyst Estimates
Metric
Annual (31 Dec 2026)
Annual (31 Dec 2027)
EPS Estimate
US$-1.01
US$-0.91
EPS Growth
+29.5%
+9.9%
Revenue Estimate
US$0.1B
US$0.1B
Revenue Growth
+9.9%
+73.0%
Number of Analysts
9
8
Valuation Ratios
| Metric | Value | Description |
|---|---|---|
| P/E Ratio (TTM) | -2.35 | The trailing twelve-month P/E ratio, calculated by dividing the current stock price by the earnings per share over the past year. A negative value indicates the company is not profitable. |
| Forward P/E | -3.71 | The forward P/E ratio, calculated by dividing the current stock price by the estimated future earnings per share. A negative value suggests analysts expect continued losses. |
| Price/Sales (TTM) | 23.98 | The Price/Sales ratio over the trailing twelve months, calculated by dividing the current market capitalization by the total revenue. It indicates how much investors are willing to pay for each dollar of sales. |
| Price/Book (MRQ) | 1.58 | The Price/Book ratio for the most recent quarter, calculated by dividing the current stock price by the company's book value per share. It shows how investors value the company's assets relative to its market price. |
| EV/EBITDA | -1.99 | The Enterprise Value to EBITDA ratio, which compares the total value of the company (market cap plus debt minus cash) to its earnings before interest, taxes, depreciation, and amortization. A negative value is common for loss-making companies. |
| Return on Equity (TTM) | -0.60 | The Return on Equity over the trailing twelve months, representing the net income divided by shareholders' equity. A negative value indicates the company is currently unprofitable and eroding equity. |
| Operating Margin | -3.29 | The operating margin, calculated as operating income divided by revenue. A negative margin indicates the company is losing money from its core operations. |